Evidence map›Paper›PMID 39198446›Full record

ArticleNature communications2024

Clonal evolution of the 3D chromatin landscape in patients with relapsed pediatric B-cell acute lymphoblastic leukemia.

Sonali Narang, Yohana Ghebrechristos, Nikki A Evensen, Nina Murrell, Sylwia Jasinski, Talia H Ostrow, David T Teachey, Elizabeth A Raetz, Timothee Lionnet, Matthew Witkowski and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sonali Narang *Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.ORCID 0000-0002-1138-0067
Yohana Ghebrechristos *Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Nikki A EvensenPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Nina MurrellPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Sylwia JasinskiPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Talia H OstrowPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
David T TeacheyDepartment of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID 0000-0001-7373-8987
Elizabeth A RaetzPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Timothee LionnetInstitute for Systems Genetics and Department of Cell Biology, NYU Langone Health, New York, NY, USA.ORCID 0000-0003-1508-0202
Matthew WitkowskiDepartment of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0003-1434-4288
Iannis AifantisPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA. Ioannis.Aifantis@nyulangone.org.
Aristotelis TsirigosPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA. aristotelis.tsirigos@nyulangone.org.ORCID 0000-0002-7512-8477
William L CarrollPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA. william.carroll@nyulangone.org.ORCID 0000-0003-1550-4167

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
The impact of changes in chromatin architecture on cancer phenotypes and tumor progressionP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 2019 to 2026
$17.0M
Drug Resistant Pathways in Relapsed Acute Lymphoblastic Leukemia(ALL)R01CA140729 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L. · 2010 to 2020
$4.8M
Targeting Epigenetic Heterogeneity in Pediatric T cell leukemia: Epi-Clones as Drivers of ChemoresistanceR01CA252239 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aristotelis Tsirigos · 2021 to 2026
$3.7M
Mechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5M
Remodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcomeR01CA260028 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LIONNET, TIMOTHEE · 2021 to 2025
$2.2M
NCI NIH HHS P01 CA229086NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA140729NCI NIH HHS R01 CA228135NCI NIH HHS R01 CA252239NCI NIH HHS R01 CA260028NCI NIH HHS U10 CA180886NCI NIH HHS U24 CA196173U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01CA229086U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA140729U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA252239U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA260028
6 · The paper itself

Abstract

Relapsed pediatric B-cell acute lymphoblastic leukemia (B-ALL) remains one of the leading causes of cancer mortality in children. We performed Hi-C, ATAC-seq, and RNA-seq on 12 matched diagnosis/relapse pediatric leukemia specimens to uncover dynamic structural variants (SVs) and 3D chromatin rewiring that may contribute to relapse. While translocations are assumed to occur early in leukemogenesis and be maintained throughout progression, we discovered novel, dynamic translocations and confirmed several fusion transcripts, suggesting functional and therapeutic relevance. Genome-wide chromatin remodeling was observed at all organizational levels: A/B compartments, TAD interactivity, and chromatin loops, including some loci shared by 25% of patients. Shared changes were found to drive the expression of genes/pathways previously implicated in resistance as well as novel therapeutic candidates, two of which (ATXN1 and MN1) we functionally validated. Overall, these results demonstrate chromatin reorganization under the selective pressure of therapy and offer the potential for discovery of novel therapeutic interventions.

Indexed as

ChromatinClonal EvolutionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolChromatin Assembly and DisassemblyFemaleHumansMaleRecurrenceTranslocation, GeneticChromatin

Identifiers

PMID39198446
PMCPMC11358475

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.